This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.
Patients (males or females) diagnosed with unresectable locally advanced or MBC (either after a recurrence or as first diagnosis) from January 2016 onwards.
Patients who died are allowed to be included on the study.
Able and willing to provide written informed consent if they are alive.
Age ≥ 18 years.
None
Spanish Breast Cancer Research Group
Lead sponsor
Hoffmann-La Roche
Collaborator
Novartis
Collaborator
AstraZeneca
Collaborator
Pfizer
Collaborator
Celgene
Collaborator